| Value | ₹0.50 Cr |
|---|---|
| Execution period | Valid up to 05 May 2027 |
NSE filing, NSE: NITIRAJ. Summary written from the filing by ALFA Finder's alert engine.
Nitiraj Engineers Ltd: key numbers
- Share price
- ₹190.20
- Market cap
- ₹195.0 Cr
- Revenue (annual)
- ₹46.41 Cr
- Net profit (annual)
- ₹1.06 Cr
- P/E (TTM)
- 81.0×Sector 41.2×
- Promoter holding
- 69.28%+0.21% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nitiraj Engineers Ltd
All →Nitiraj Engineers Management Change
Nitiraj Engineers Limited has announced the re-appointment of Mr. Yi Hung Sin as an Executive Director for a five-year term, effective September 28, 2026.
Nitiraj Engineers Annual General Meeting
Nitiraj Engineers Limited conducted its 27th Annual General Meeting on September 28, 2026. The meeting covered routine items including financial statement adoption and auditor remuneration.
Nitiraj Engineers Other Announcement
Nitiraj Engineers informed shareholders with unregistered emails about accessing the AGM notice and Annual Report for FY 2025-26 via its website.
Nitiraj Engineers Annual General Meeting
Nitiraj Engineers approved its Annual Report and scheduled the 27th Annual General Meeting for September 28, 2026.
Nitiraj Engineers Board Meeting Date
Nitiraj Engineers Limited has scheduled a board meeting for September 4, 2026. The meeting agenda includes the consideration of various other business matters.
Nitiraj Engineers Q1 FY27 Results: Turns Profitable, Net Profit ₹1 Cr
Nitiraj Engineers Ltd reported revenue from operations of ₹18.8 Cr (+79.0% YoY) and net profit of ₹1 Cr for Q1 FY27.
- Key figure
- Net profit ₹1 Cr
Other regulatory approval announcements
All →Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.
Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.